胃がん治療薬市場：分子タイプ、化学療法ライン、投与経路別-2025-2030年の世界予測

胃がん治療薬市場は、2023年に38億3,000万米ドルと評価され、2024年には40億6,000万米ドルに達すると予測され、CAGR 6.14％で成長し、2030年には58億1,000万米ドルに達すると予測されています。

胃がん治療薬の対象範囲には、胃の粘膜組織を侵す胃がんを治療するための治療法の開発、製造、応用が含まれます。これには、化学療法、標的療法、免疫療法薬が含まれます。これらの薬剤の必要性が高まっている背景には、世界の胃がん罹患率の上昇があり、患者の生存率と生活の質を向上させるために、より効果的な治療が必要となっています。治療は主に、病院や診療所を含むヘルスケアプロバイダーや、治療技術の進歩を探求する研究機関に焦点を当てています。最終用途の範囲は製薬会社、研究機関、医療機関にも及び、先進治療をがん治療プロトコルに組み込むことを目指しています。

市場の洞察により、胃がんの症状に対する意識の高まり、薬効を高めるバイオテクノロジーの進歩、がん研究への資金提供の可能性などの主要成長要因が明らかになった。アジア太平洋地域、特に中国と日本は、有病率の高さとヘルスケア支出の増加により、大きな可能性を秘めています。チャンスを生かすための提言としては、製薬企業とバイオ新興企業との戦略的提携、新規治療法の研究開発への投資拡大などがあります。

しかし、多額の研究開発コストや、医薬品の上市を遅らせる可能性のある厳しい規制当局の承認といった制約も存在します。さらに、薬剤耐性や患者間の治療効果のばらつきといった課題にも直面しています。これらを克服するためには、個別化医療に焦点を当て、適応臨床試験を実施することが非常に有益です。

技術革新が必要な分野には、治療効果を相乗的に高める併用療法の開発や、早期診断と個別化治療計画のためのAIの活用などがあります。遺伝的素因を理解するためにゲノミクスの進歩を利用することも、製品の差別化を促進する可能性があります。全体として、競合情勢に対応し、患者中心のソリューションに投資することができれば、市場情勢は競争的でありながら有望であり、技術革新と戦略的提携による成長の余地が大きいです。

市場力学：急速に進化する胃がん治療薬市場の主要市場インサイトを公開

胃がん治療薬市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができ、また、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 肥満症例と喫煙人口の増加に伴う胃がん罹患率の上昇
  • 転移性胃がんに対する新規治療法のイントロダクション
  • 胃がんの症状や原因に関する認知度の向上
• 市場抑制要因
  • 医薬品の承認に関する厳しい規制と政策
• 市場機会
  • 胃がん治療薬の研究開発の加速
  • がん領域におけるバイオシミラーの急速な普及
• 市場の課題
  • 偽造医薬品の入手可能性

ポーターの5つの力：胃がん治療薬市場をナビゲートする戦略ツール

ポーターの5つの力」フレームワークは、市場情勢の競合情勢を把握するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：胃がん治療薬市場における外部からの影響の把握

外部マクロ環境要因は、胃がん治療薬市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析胃がん治療薬市場における競合情勢の把握

胃がん治療薬市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス胃がん治療薬市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、胃がん治療薬市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨胃がん治療薬市場における成功への道筋を描く

胃がん治療薬市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を検討することで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報に基づいた意思決定を行う上で役立つ重要な質問にも回答しています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 肥満や喫煙者の増加に伴い胃がんの発生率が上昇
    • 転移性胃がんに対する新しい治療法のイントロダクション
    • 胃がんの症状と原因についての認識の向上
  • 抑制要因
    • 医薬品の承認に関する厳格な規制と政策
  • 機会
    • 胃がん治療薬の研究開発を加速
    • 腫瘍学におけるバイオシミラーの急速な導入
  • 課題
    • 偽造医薬品の入手可能性
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 胃がん治療薬市場分子タイプ別

• 生物学的製剤
• 小分子

第7章 胃がん治療薬市場化学療法ライン

• 第一選択化学療法
• 第二選択化学療法

第8章 胃がん治療薬市場：投与経路別

• オーラル
• 非経口

第9章 南北アメリカの胃がん治療薬市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋地域の胃がん治療薬市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカの胃がん治療薬市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Amgen Inc.
• ASLAN Pharmaceuticals Pte Ltd
• AstraZeneca PLC
• Bayer AG
• Bristol Myers Squibb Company
• Eli Lilly and Company
• F. Hoffmann-La Roche AG
• GlaxoSmithKline PLC
• Jiangsu Hengrui Pharmaceuticals Co., Ltd.
• Merck & Co., Inc.
• Novartis AG
• Pfizer Inc.
• SELLAS Life Sciences Group, Inc.
• Taiho Pharmaceutical Co., Ltd.
• Takeda Pharmaceutical Company Limited

LIST OF FIGURES

• FIGURE 1. GASTRIC CANCER DRUGS MARKET RESEARCH PROCESS
• FIGURE 2. GASTRIC CANCER DRUGS MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY LINES OF CHEMOTHERAPY, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY LINES OF CHEMOTHERAPY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. AMERICAS GASTRIC CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 13. AMERICAS GASTRIC CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. UNITED STATES GASTRIC CANCER DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 15. UNITED STATES GASTRIC CANCER DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC GASTRIC CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. ASIA-PACIFIC GASTRIC CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA GASTRIC CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA GASTRIC CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. GASTRIC CANCER DRUGS MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 21. GASTRIC CANCER DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. GASTRIC CANCER DRUGS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. GASTRIC CANCER DRUGS MARKET DYNAMICS
• TABLE 7. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY SMALL MOLECULES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY LINES OF CHEMOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY FIRST-LINE CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY SECOND-LINE CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. AMERICAS GASTRIC CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 17. AMERICAS GASTRIC CANCER DRUGS MARKET SIZE, BY LINES OF CHEMOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 18. AMERICAS GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 19. AMERICAS GASTRIC CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 20. ARGENTINA GASTRIC CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 21. ARGENTINA GASTRIC CANCER DRUGS MARKET SIZE, BY LINES OF CHEMOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 22. ARGENTINA GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 23. BRAZIL GASTRIC CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 24. BRAZIL GASTRIC CANCER DRUGS MARKET SIZE, BY LINES OF CHEMOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 25. BRAZIL GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 26. CANADA GASTRIC CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 27. CANADA GASTRIC CANCER DRUGS MARKET SIZE, BY LINES OF CHEMOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 28. CANADA GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 29. MEXICO GASTRIC CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 30. MEXICO GASTRIC CANCER DRUGS MARKET SIZE, BY LINES OF CHEMOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 31. MEXICO GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 32. UNITED STATES GASTRIC CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 33. UNITED STATES GASTRIC CANCER DRUGS MARKET SIZE, BY LINES OF CHEMOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 34. UNITED STATES GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 35. UNITED STATES GASTRIC CANCER DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 36. ASIA-PACIFIC GASTRIC CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 37. ASIA-PACIFIC GASTRIC CANCER DRUGS MARKET SIZE, BY LINES OF CHEMOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 38. ASIA-PACIFIC GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 39. ASIA-PACIFIC GASTRIC CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 40. AUSTRALIA GASTRIC CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 41. AUSTRALIA GASTRIC CANCER DRUGS MARKET SIZE, BY LINES OF CHEMOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 42. AUSTRALIA GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 43. CHINA GASTRIC CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 44. CHINA GASTRIC CANCER DRUGS MARKET SIZE, BY LINES OF CHEMOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 45. CHINA GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 46. INDIA GASTRIC CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 47. INDIA GASTRIC CANCER DRUGS MARKET SIZE, BY LINES OF CHEMOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 48. INDIA GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 49. INDONESIA GASTRIC CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 50. INDONESIA GASTRIC CANCER DRUGS MARKET SIZE, BY LINES OF CHEMOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 51. INDONESIA GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 52. JAPAN GASTRIC CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 53. JAPAN GASTRIC CANCER DRUGS MARKET SIZE, BY LINES OF CHEMOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 54. JAPAN GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 55. MALAYSIA GASTRIC CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 56. MALAYSIA GASTRIC CANCER DRUGS MARKET SIZE, BY LINES OF CHEMOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 57. MALAYSIA GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 58. PHILIPPINES GASTRIC CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 59. PHILIPPINES GASTRIC CANCER DRUGS MARKET SIZE, BY LINES OF CHEMOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 60. PHILIPPINES GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 61. SINGAPORE GASTRIC CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 62. SINGAPORE GASTRIC CANCER DRUGS MARKET SIZE, BY LINES OF CHEMOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 63. SINGAPORE GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 64. SOUTH KOREA GASTRIC CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 65. SOUTH KOREA GASTRIC CANCER DRUGS MARKET SIZE, BY LINES OF CHEMOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 66. SOUTH KOREA GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 67. TAIWAN GASTRIC CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 68. TAIWAN GASTRIC CANCER DRUGS MARKET SIZE, BY LINES OF CHEMOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 69. TAIWAN GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 70. THAILAND GASTRIC CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 71. THAILAND GASTRIC CANCER DRUGS MARKET SIZE, BY LINES OF CHEMOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 72. THAILAND GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 73. VIETNAM GASTRIC CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 74. VIETNAM GASTRIC CANCER DRUGS MARKET SIZE, BY LINES OF CHEMOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 75. VIETNAM GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 76. EUROPE, MIDDLE EAST & AFRICA GASTRIC CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 77. EUROPE, MIDDLE EAST & AFRICA GASTRIC CANCER DRUGS MARKET SIZE, BY LINES OF CHEMOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 78. EUROPE, MIDDLE EAST & AFRICA GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 79. EUROPE, MIDDLE EAST & AFRICA GASTRIC CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 80. DENMARK GASTRIC CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 81. DENMARK GASTRIC CANCER DRUGS MARKET SIZE, BY LINES OF CHEMOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 82. DENMARK GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 83. EGYPT GASTRIC CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 84. EGYPT GASTRIC CANCER DRUGS MARKET SIZE, BY LINES OF CHEMOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 85. EGYPT GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 86. FINLAND GASTRIC CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 87. FINLAND GASTRIC CANCER DRUGS MARKET SIZE, BY LINES OF CHEMOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 88. FINLAND GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 89. FRANCE GASTRIC CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 90. FRANCE GASTRIC CANCER DRUGS MARKET SIZE, BY LINES OF CHEMOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 91. FRANCE GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 92. GERMANY GASTRIC CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 93. GERMANY GASTRIC CANCER DRUGS MARKET SIZE, BY LINES OF CHEMOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 94. GERMANY GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 95. ISRAEL GASTRIC CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 96. ISRAEL GASTRIC CANCER DRUGS MARKET SIZE, BY LINES OF CHEMOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 97. ISRAEL GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 98. ITALY GASTRIC CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 99. ITALY GASTRIC CANCER DRUGS MARKET SIZE, BY LINES OF CHEMOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 100. ITALY GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 101. NETHERLANDS GASTRIC CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 102. NETHERLANDS GASTRIC CANCER DRUGS MARKET SIZE, BY LINES OF CHEMOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 103. NETHERLANDS GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 104. NIGERIA GASTRIC CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 105. NIGERIA GASTRIC CANCER DRUGS MARKET SIZE, BY LINES OF CHEMOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 106. NIGERIA GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 107. NORWAY GASTRIC CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 108. NORWAY GASTRIC CANCER DRUGS MARKET SIZE, BY LINES OF CHEMOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 109. NORWAY GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 110. POLAND GASTRIC CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 111. POLAND GASTRIC CANCER DRUGS MARKET SIZE, BY LINES OF CHEMOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 112. POLAND GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 113. QATAR GASTRIC CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 114. QATAR GASTRIC CANCER DRUGS MARKET SIZE, BY LINES OF CHEMOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 115. QATAR GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 116. RUSSIA GASTRIC CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 117. RUSSIA GASTRIC CANCER DRUGS MARKET SIZE, BY LINES OF CHEMOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 118. RUSSIA GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 119. SAUDI ARABIA GASTRIC CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 120. SAUDI ARABIA GASTRIC CANCER DRUGS MARKET SIZE, BY LINES OF CHEMOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 121. SAUDI ARABIA GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 122. SOUTH AFRICA GASTRIC CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 123. SOUTH AFRICA GASTRIC CANCER DRUGS MARKET SIZE, BY LINES OF CHEMOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 124. SOUTH AFRICA GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 125. SPAIN GASTRIC CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 126. SPAIN GASTRIC CANCER DRUGS MARKET SIZE, BY LINES OF CHEMOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 127. SPAIN GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 128. SWEDEN GASTRIC CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 129. SWEDEN GASTRIC CANCER DRUGS MARKET SIZE, BY LINES OF CHEMOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 130. SWEDEN GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 131. SWITZERLAND GASTRIC CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 132. SWITZERLAND GASTRIC CANCER DRUGS MARKET SIZE, BY LINES OF CHEMOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 133. SWITZERLAND GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 134. TURKEY GASTRIC CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 135. TURKEY GASTRIC CANCER DRUGS MARKET SIZE, BY LINES OF CHEMOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 136. TURKEY GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 137. UNITED ARAB EMIRATES GASTRIC CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 138. UNITED ARAB EMIRATES GASTRIC CANCER DRUGS MARKET SIZE, BY LINES OF CHEMOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 139. UNITED ARAB EMIRATES GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 140. UNITED KINGDOM GASTRIC CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 141. UNITED KINGDOM GASTRIC CANCER DRUGS MARKET SIZE, BY LINES OF CHEMOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 142. UNITED KINGDOM GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 143. GASTRIC CANCER DRUGS MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 144. GASTRIC CANCER DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

The Gastric Cancer Drugs Market was valued at USD 3.83 billion in 2023, expected to reach USD 4.06 billion in 2024, and is projected to grow at a CAGR of 6.14%, to USD 5.81 billion by 2030.

The scope of gastric cancer drugs encompasses the development, production, and application of therapies designed to treat gastric cancer, which affects the stomach's mucosal tissue. This includes chemotherapy, targeted therapy, and immunotherapy drugs. The increasing necessity for these drugs is driven by the rising incidence of gastric cancer globally, necessitating more effective treatments to improve patient survival rates and life quality. Applications primarily focus on healthcare providers, including hospitals and clinics, along with research institutions exploring advancements in treatment techniques. End-use scope extends to pharmaceutical companies, research bodies, and medical institutions, aiming to integrate advanced treatments into cancer care protocols.

Market insights reveal key growth factors such as heightened awareness of gastric cancer symptoms, advancements in biotechnology enhancing drug efficacy, and the availability of funding for cancer research. The Asia-Pacific region, particularly China and Japan, presents significant potential due to high prevalence rates and increasing healthcare expenditure. Recommendations to capitalize on opportunities include strategic partnerships between pharmaceutical firms and biotech startups, and increased investment in R&D for novel treatment options.

However, limitations exist in the form of substantial R&D costs and stringent regulatory approvals that can delay drug launches. Additionally, the market faces challenges such as drug resistance and variability in treatment responses among patients. To overcome these, focusing on personalized medicine and implementing adaptive clinical trials could be highly beneficial.

Areas ripe for innovation include the development of combination therapies that synergistically enhance treatment effectiveness, as well as leveraging AI for early diagnosis and personalized treatment plans. Exploiting advancements in genomics to understand genetic predispositions could also foster product differentiation. Overall, the gastric cancer drugs market is competitive yet promising, with significant scope for growth through technological innovations and strategic alliances, provided that businesses can navigate the regulatory landscape and invest in patient-centric solutions.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Gastric Cancer Drugs Market

The Gastric Cancer Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Rising incidences of the stomach cancer with the increasing number of obesity cases and smoking population
  • Introduction of novel therapies for metastatic stomach cancer
  • Increase in awareness about the symptoms and causes of gastric cancer
• Market Restraints
  • Stringent regulations and policies for approval of the drugs
• Market Opportunities
  • Accelerating research and development activities in the drugs for gastic cancer
  • Rapid adoption of biosimilars in oncology
• Market Challenges
  • Availability of the counterfeit drugs

Porter's Five Forces: A Strategic Tool for Navigating the Gastric Cancer Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Gastric Cancer Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Gastric Cancer Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Gastric Cancer Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Gastric Cancer Drugs Market

A detailed market share analysis in the Gastric Cancer Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Gastric Cancer Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Gastric Cancer Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Gastric Cancer Drugs Market

A strategic analysis of the Gastric Cancer Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Gastric Cancer Drugs Market, highlighting leading vendors and their innovative profiles. These include Amgen Inc., ASLAN Pharmaceuticals Pte Ltd, AstraZeneca PLC, Bayer AG, Bristol Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche AG, GlaxoSmithKline PLC, Jiangsu Hengrui Pharmaceuticals Co., Ltd., Merck & Co., Inc., Novartis AG, Pfizer Inc., SELLAS Life Sciences Group, Inc., Taiho Pharmaceutical Co., Ltd., and Takeda Pharmaceutical Company Limited.

Market Segmentation & Coverage

This research report categorizes the Gastric Cancer Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Molecule Type, market is studied across Biologics and Small Molecules.
• Based on Lines of Chemotherapy, market is studied across First-line Chemotherapy and Second-line Chemotherapy.
• Based on Route of Administration, market is studied across Oral and Parenteral.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising incidences of the stomach cancer with the increasing number of obesity cases and smoking population
    • 5.1.1.2. Introduction of novel therapies for metastatic stomach cancer
    • 5.1.1.3. Increase in awareness about the symptoms and causes of gastric cancer
  • 5.1.2. Restraints
    • 5.1.2.1. Stringent regulations and policies for approval of the drugs
  • 5.1.3. Opportunities
    • 5.1.3.1. Accelerating research and development activities in the drugs for gastic cancer
    • 5.1.3.2. Rapid adoption of biosimilars in oncology
  • 5.1.4. Challenges
    • 5.1.4.1. Availability of the counterfeit drugs
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Gastric Cancer Drugs Market, by Molecule Type

• 6.1. Introduction
• 6.2. Biologics
• 6.3. Small Molecules

7. Gastric Cancer Drugs Market, by Lines of Chemotherapy

• 7.1. Introduction
• 7.2. First-line Chemotherapy
• 7.3. Second-line Chemotherapy

8. Gastric Cancer Drugs Market, by Route of Administration

• 8.1. Introduction
• 8.2. Oral
• 8.3. Parenteral

9. Americas Gastric Cancer Drugs Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Gastric Cancer Drugs Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Gastric Cancer Drugs Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Amgen Inc.
• 2. ASLAN Pharmaceuticals Pte Ltd
• 3. AstraZeneca PLC
• 4. Bayer AG
• 5. Bristol Myers Squibb Company
• 6. Eli Lilly and Company
• 7. F. Hoffmann-La Roche AG
• 8. GlaxoSmithKline PLC
• 9. Jiangsu Hengrui Pharmaceuticals Co., Ltd.
• 10. Merck & Co., Inc.
• 11. Novartis AG
• 12. Pfizer Inc.
• 13. SELLAS Life Sciences Group, Inc.
• 14. Taiho Pharmaceutical Co., Ltd.
• 15. Takeda Pharmaceutical Company Limited